Known targets — ChEMBL curated mechanism
ACEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ATP4AATP4BAXLBTKCACNA1CCACNA1DCACNA1FCACNA1SCCR5CHRM2CHRM3CPT1BCPT2DPP4DRD1DRD2EGFRERBB2ERBB4FLT3HRH1HRH3HTR1AHTR2AHTR2BHTR2CHTR4JAK1JAK2JAK3KCNH2KMT2AMAP2K1MAP2K2MEN1MLNRMPLMTORPPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PLK4PPARGRENS1PR1SLC6A2SLC6A3SLC6A4SMOTYK2atpAatpBatpCatpDatpEatpFatpFHatpGpol
The experimentally established mechanism targets of Fumaric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 known ✓ | Q12809 | 1/20 | 0.38 |
| ▸ | HTR4 known ✓ | Q13639 | 1/20 | 0.33 |
| ▸ | HTR1A known ✓ | P08908 | 2/20 | 0.33 |
| ▸ | ADRA1A known ✓ | P35348 | 2/20 | 0.33 |
| ▸ | DRD2 known ✓ | P14416 | 1/20 | 0.33 |
| ▸ | HTR3E | A5X5Y0 | 2/20 | 0.44 |
| ▸ | HTR3B | O95264 | 2/20 | 0.44 |
| ▸ | HTR3A | P46098 | 2/20 | 0.44 |
| ▸ | HTR3D | Q70Z44 | 2/20 | 0.44 |
| ▸ | HTR3C | Q8WXA8 | 2/20 | 0.44 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.33 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.33 |
| ▸ | SLC6A9 | P48067 | 5/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.32 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fumaric Acid SCHEMBL16097773 | 1.00 | HTR3E (0.44) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL16102963 | 0.95 | HTR3E (0.48) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| Hydrochloric Acid SCHEMBL16097867 | 0.94 | HTR3E (0.47) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL18101485 | 0.89 | HTR3E (0.48) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL16123528 | 0.88 | KCNH2 (0.38) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL16102006 | 0.87 | HTR3E (0.44) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL18094608 | 0.87 | HTR3E (0.46) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL18094618 | 0.86 | KCNH2 (0.38) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL18094621 | 0.86 | KCNH2 (0.37) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL18094593 | 0.85 | HTR3E (0.45) | HTR3EHTR3BHTR3AHTR3DHTR3C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9790211-B2 | 5-amino-quinoline-8-carboxamide derivatives as 5-HT4 receptor agonists | SUVEN LIFE SCIENCES LIMITED (IN) | 2017-10-17 | — | — | US | claimed |
| EP-2976337-A1 | 5-AMINO-QUINOLINE-8-CARBOXAMIDE DERIVATIVES AS 5-HT4 RECEPTOR AGONISTS | Suven Life Sciences Limited (IN) | 2016-01-27 | — | — | EP | claimed |
| WO-2014147636-A1 | 5-AMINO-QUINOLINE-8-CARBOXAMIDE DERIVATIVES AS 5-HT4 RECEPTOR AGONISTS | SUVEN LIFE SCIENCES LIMITED (IN) | 2014-09-25 | — | — | WO | claimed |
| EP-2976337-B1 | 5-AMINO-QUINOLINE-8-CARBOXAMIDE DERIVATIVES AS 5-HT4 RECEPTOR AGONISTS | SUVEN LIFE SCIENCES LTD (IN) | 2018-05-02 | — | — | EP | disclosed |
| US-9790211-B2 | 5-amino-quinoline-8-carboxamide derivatives as 5-HT4 receptor agonists | SUVEN LIFE SCIENCES LIMITED (IN) | 2017-10-17 | — | — | US | disclosed |
| US-20160280694-A1 | 5-AMINO-QUINOLINE-8-CARBOXAMIDE DERIVATIVES AS 5-HT4 RECEPTOR AGONISTS | SUVEN LIFE SCIENCES LIMITED (IN) | 2016-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160280694-A1 | 5-AMINO-QUINOLINE-8-CARBOXAMIDE DERIVATIVES AS 5-HT4 RECEPTOR AGONISTS | HTR4, HTR5A, HTR1A | KCNH2 725/4885HTR4 1/4885HTR1A 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.